Literature DB >> 15080860

Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS.

T Pirttilä1, S Vanhatalo, U Turpeinen, R Riikonen.   

Abstract

OBJECTIVES: Many studies have shown that nitric oxide (NO) and growth factors including insulin growth factors (IGFs) may be involved in the pathogenesis of multiple sclerosis (MS) and neurodegenerative diseases. Our previous studies suggested a relationship between cerebrospinal fluid (CSF) NO metabolites (nitrates and nitrites, NN(x)) and IGF-1 in patients with progressive encephalopathy, hypsarrhythmia and optic atrophy syndrome.
MATERIAL AND METHODS: We examined CSF concentrations of NN(x), IGF-1 and IGF binding protein-2 (IGFBP-2) in 25 controls, 14 patients with MS and 14 patients with amyotrophic lateralis sclerosis (ALS).
RESULTS: There were no significant differences in CSF levels of NN(x), IGF-1 or IGFBP-2 between the groups. CSF IGFBP-2 concentrations correlated significantly with age in controls, which may reflect age-related changes in the blood-brain barrier function.
CONCLUSION: Upregulation of the production of NO and IGF-1 in the brain or spinal cord does not influence CSF levels of these molecules in MS or ALS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15080860     DOI: 10.1111/j.1600-0404.2004.00223.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  14 in total

Review 1.  The role of growth factors as a therapeutic approach to demyelinating disease.

Authors:  Yangyang Huang; Cheryl F Dreyfus
Journal:  Exp Neurol       Date:  2016-03-22       Impact factor: 5.330

Review 2.  CSF markers in amyotrophic lateral sclerosis.

Authors:  Joanna Tarasiuk; Alina Kułakowska; Wiesław Drozdowski; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-05-04       Impact factor: 3.575

Review 3.  Potential new complication in drug therapy development for amyotrophic lateral sclerosis.

Authors:  Svitlana Garbuzova-Davis; Avery Thomson; Crupa Kurien; R Douglas Shytle; Paul R Sanberg
Journal:  Expert Rev Neurother       Date:  2016-07-15       Impact factor: 4.618

4.  Reduction of elevated IGF-1 levels in coincident amyotrophic lateral sclerosis and acromegaly.

Authors:  Erlick A C Pereira; Martin R Turner; John A H Wass; Kevin Talbot
Journal:  Amyotroph Lateral Scler       Date:  2010

5.  Immunohistochemical localization of insulin-like growth factor binding protein 2 in the central nervous system of SOD1(G93A) transgenic mice.

Authors:  Sung Eun Sim; Yoon Hee Chung; Ji Hoon Jeong; Sin Weon Yun; Hyoun-Sub Lim; Daejin Kim; Sung Su Kim; Won Bok Lee; Choong Ik Cha
Journal:  J Mol Histol       Date:  2009-05-26       Impact factor: 2.611

6.  Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS.

Authors:  Svitlana Garbuzova-Davis; Samuel Saporta; Edward Haller; Irina Kolomey; Steven P Bennett; Huntington Potter; Paul R Sanberg
Journal:  PLoS One       Date:  2007-11-21       Impact factor: 3.240

7.  The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer's Disease.

Authors:  Ian James Martins
Journal:  Proteomes       Date:  2016-03-31

8.  Global alterations to the choroid plexus blood-CSF barrier in amyotrophic lateral sclerosis.

Authors:  J Saul; E Hutchins; R Reiman; M Saul; L W Ostrow; B T Harris; K Van Keuren-Jensen; R Bowser; N Bakkar
Journal:  Acta Neuropathol Commun       Date:  2020-06-26       Impact factor: 7.801

9.  Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis.

Authors:  Ethan A Winkler; Jesse D Sengillo; John S Sullivan; Jenny S Henkel; Stanley H Appel; Berislav V Zlokovic
Journal:  Acta Neuropathol       Date:  2012-09-01       Impact factor: 17.088

10.  Serum insulin-like growth factor-1 and nitric oxide levels in Parkinson's disease.

Authors:  Deniz Tuncel; Fatma Inanc Tolun; Ismail Toru
Journal:  Mediators Inflamm       Date:  2009-03-12       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.